The expression of ocular biomarkers provides valuable information for predicting and investigating the efficacy of new ocular therapies during preclinical and clinical research
Our multidisciplinary team of scientists works with our customers to identify and quantify predictive ocular biomarkers – such as those involved in neovascularization and the inflammation - in many animal models.
Dry eye syndrome is a multifactorial disease on the ocular surface, leading to conjunctival inflammation associated with expression of biomarkers such as HLA-DR (Human Leukocyte Antigen).
HLA-DR quantification is very interesting in clinical trials related to ocular surface diseases and is used in the US and EU as an ancillary parameter to be considered.
HLA-DR quantification by flow cytometry has been developed and mastered by our expert since 1997.
Iris Pharma has a laboratory equiped with cutting-edge technologies for cellular and molecular biology assays (flow cytometry, RT-qPCR, ELISA and Multiplex).